GS
follow link to MSigDB
GS DETAILSSIZEESNESNOM p-valFDR q-valFWER p-valRANK AT MAXLEADING EDGE
1FISCHER_DREAM_TARGETSDetails ...16-0.58-1.780.0000.1770.00070tags=56%, list=27%, signal=73%
2PATIL_LIVER_CANCERDetails ...17-0.62-1.690.0000.1770.17766tags=53%, list=26%, signal=67%
3CHICAS_RB1_TARGETS_CONFLUENTDetails ...27-0.72-1.580.0000.3330.49542tags=59%, list=16%, signal=63%
4WANG_SMARCE1_TARGETS_UPDetails ...16-0.53-1.540.0000.3560.49554tags=50%, list=21%, signal=59%
5SENESE_HDAC3_TARGETS_UPDetails ...17-0.37-1.520.0000.3200.49548tags=29%, list=19%, signal=34%
6DODD_NASOPHARYNGEAL_CARCINOMA_DNDetails ...36-0.43-1.480.0000.3540.65870tags=39%, list=27%, signal=46%
7JOHNSTONE_PARVB_TARGETS_3_DNDetails ...18-0.66-1.410.0000.4790.82330tags=33%, list=12%, signal=35%
8GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DNDetails ...27-0.57-1.410.0000.4420.82332tags=30%, list=13%, signal=30%
9BENPORATH_EED_TARGETSDetails ...23-0.54-1.390.0000.4120.82343tags=39%, list=17%, signal=43%
10NUYTTEN_NIPP1_TARGETS_DNDetails ...23-0.56-1.380.0000.3890.82355tags=39%, list=22%, signal=45%
11CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_DNDetails ...22-0.46-1.360.0000.4020.82362tags=50%, list=24%, signal=60%
12RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DNDetails ...20-0.51-1.330.0000.4120.82357tags=35%, list=22%, signal=42%
13NUYTTEN_EZH2_TARGETS_UPDetails ...15-0.40-1.320.0000.4130.82353tags=40%, list=21%, signal=48%
14NUYTTEN_EZH2_TARGETS_DNDetails ...21-0.60-1.320.0000.3960.82378tags=67%, list=31%, signal=88%
15LEE_BMP2_TARGETS_DNDetails ...20-0.47-1.320.0000.3820.82352tags=30%, list=20%, signal=35%
16DUTERTRE_ESTRADIOL_RESPONSE_24HR_DNDetails ...19-0.52-1.310.0000.3840.82362tags=53%, list=24%, signal=64%
17REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATIONDetails ...18-0.40-1.300.0000.3720.82373tags=44%, list=29%, signal=58%
18BENPORATH_SUZ12_TARGETSDetails ...22-0.46-1.270.0000.4000.82353tags=41%, list=21%, signal=47%
19KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_UPDetails ...16-0.58-1.250.0000.4200.82375tags=56%, list=29%, signal=75%
20DACOSTA_UV_RESPONSE_VIA_ERCC3_DNDetails ...23-0.47-1.250.0000.4080.82362tags=43%, list=24%, signal=52%
21KRIGE_RESPONSE_TO_TOSEDOSTAT_6HR_UP18-0.52-1.250.0000.4130.82375tags=50%, list=29%, signal=66%
22BENPORATH_SOX2_TARGETS16-0.58-1.230.0000.4130.82366tags=50%, list=26%, signal=63%
23BLALOCK_ALZHEIMERS_DISEASE_DN20-0.39-1.230.0000.4130.82353tags=35%, list=21%, signal=41%
24ENK_UV_RESPONSE_EPIDERMIS_DN15-0.43-1.210.0000.4130.82355tags=27%, list=22%, signal=32%
25BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN21-0.38-1.190.0000.5201.00063tags=43%, list=25%, signal=52%
26REACTOME_DEVELOPMENTAL_BIOLOGY17-0.45-1.180.0000.5431.00054tags=35%, list=21%, signal=42%
27KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_UP25-0.49-1.180.0000.5291.00052tags=32%, list=20%, signal=36%
28ONDER_CDH1_TARGETS_2_UP19-0.46-1.180.3270.5251.00062tags=53%, list=24%, signal=64%
29DIAZ_CHRONIC_MEYLOGENOUS_LEUKEMIA_UP25-0.35-1.170.3350.5251.00063tags=28%, list=25%, signal=34%
30KOINUMA_TARGETS_OF_SMAD2_OR_SMAD323-0.29-1.170.3230.5141.00066tags=26%, list=26%, signal=32%
31BENPORATH_ES_WITH_H3K27ME325-0.43-1.160.0000.5401.00043tags=28%, list=17%, signal=30%
32REACTOME_NERVOUS_SYSTEM_DEVELOPMENT15-0.41-1.120.3250.6591.00054tags=33%, list=21%, signal=40%
33MILI_PSEUDOPODIA_HAPTOTAXIS_DN19-0.48-1.120.3350.6441.00036tags=32%, list=14%, signal=34%
34KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_DN15-0.36-1.120.0000.6311.00070tags=33%, list=27%, signal=43%
35NABA_MATRISOME23-0.51-1.100.3310.6351.00037tags=35%, list=15%, signal=37%
36ZWANG_CLASS_1_TRANSIENTLY_INDUCED_BY_EGF18-0.39-1.090.0000.6221.00019tags=22%, list=7%, signal=22%
37SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_UP17-0.50-1.090.3070.6101.00025tags=29%, list=10%, signal=30%
38MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME324-0.49-1.080.0000.5991.00049tags=50%, list=19%, signal=56%
39GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN24-0.36-1.060.0000.5941.00032tags=21%, list=13%, signal=22%
40BENPORATH_NANOG_TARGETS24-0.48-1.050.0000.5831.00066tags=42%, list=26%, signal=51%
41THUM_SYSTOLIC_HEART_FAILURE_UP18-0.40-1.030.0000.6081.00037tags=33%, list=15%, signal=36%
42WAKABAYASHI_ADIPOGENESIS_PPARG_BOUND_8D15-0.42-1.010.3070.6511.00098tags=53%, list=38%, signal=82%
43PUJANA_ATM_PCC_NETWORK23-0.36-1.010.3270.6401.00066tags=30%, list=26%, signal=37%
44MASSARWEH_TAMOXIFEN_RESISTANCE_UP16-0.55-0.990.3230.6351.00072tags=50%, list=28%, signal=65%
45FORTSCHEGGER_PHF8_TARGETS_DN15-0.34-0.990.3250.6251.00062tags=40%, list=24%, signal=50%
46BLALOCK_ALZHEIMERS_DISEASE_UP28-0.35-0.990.3350.6151.00057tags=29%, list=22%, signal=33%
47PUJANA_BRCA1_PCC_NETWORK19-0.39-0.980.3270.6061.00066tags=32%, list=26%, signal=39%
48MARSON_BOUND_BY_FOXP3_STIMULATED23-0.29-0.960.3270.6571.00052tags=26%, list=20%, signal=30%
49PEREZ_TP53_TARGETS17-0.37-0.940.6500.7371.00047tags=35%, list=18%, signal=40%
50YOSHIMURA_MAPK8_TARGETS_UP15-0.47-0.920.3310.7311.00049tags=40%, list=19%, signal=47%
51GOZGIT_ESR1_TARGETS_DN23-0.30-0.900.3270.7551.00092tags=43%, list=36%, signal=62%
52BRUINS_UVC_RESPONSE_LATE23-0.30-0.900.3250.7491.00068tags=39%, list=27%, signal=49%
53RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP16-0.45-0.890.6400.7491.00032tags=31%, list=13%, signal=33%
54GRYDER_PAX3FOXO1_ENHANCERS_IN_TADS29-0.22-0.860.3270.7601.00073tags=34%, list=29%, signal=43%
55DODD_NASOPHARYNGEAL_CARCINOMA_UP19-0.42-0.860.3250.7491.00058tags=37%, list=23%, signal=44%
56MARSON_BOUND_BY_FOXP3_UNSTIMULATED24-0.31-0.850.6500.7471.00052tags=29%, list=20%, signal=33%
57WEI_MYCN_TARGETS_WITH_E_BOX15-0.28-0.840.3070.7641.00052tags=20%, list=20%, signal=24%
58REACTOME_RNA_POLYMERASE_II_TRANSCRIPTION20-0.21-0.820.6420.7671.00044tags=15%, list=17%, signal=17%
59CUI_TCF21_TARGETS_2_DN21-0.27-0.750.6420.8431.00025tags=14%, list=10%, signal=15%
60ACEVEDO_LIVER_CANCER_UP16-0.27-0.740.6400.8421.00029tags=13%, list=11%, signal=13%
61ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN16-0.32-0.710.6400.8511.00048tags=19%, list=19%, signal=22%
62ZWANG_TRANSIENTLY_UP_BY_2ND_EGF_PULSE_ONLY19-0.36-0.690.6520.8551.00054tags=32%, list=21%, signal=37%
Table: Gene sets enriched in phenotype Pro (2 samples) [plain text format]